Search

Your search keyword '"Foss, Francine"' showing total 1,210 results
Start Over Author "Foss, Francine"
1,210 results on '"Foss, Francine"'

3. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

Author

Witzig, Thomas, Sokol, Lubomir, Kim, Won Seog, de la Cruz Vicente, Fátima, Martín García-Sancho, Alejandro, Advani, Ranjana, Roncero Vidal, Jose Maria, de Oña Navarrete, Raquel, Marín-Niebla, Ana, Rodriguez Izquierdo, Antonia, Terol, María José, Domingo-Domenech, Eva, Saunders, Andrew, Bendris, Nawal, Mackey, Julie, Leoni, Mollie, and Foss, Francine

Published
2024
Full Text
View/download PDF

4. Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas

Author

Koh, Min Jung, Merrill, Mwanasha H, Koh, Min Ji, Stuver, Robert, Alonso, Carolyn D, Foss, Francine M, Mayor, Angel M, Gill, John, Epeldegui, Marta, Cachay, Edward, Thorne, Jennifer E, Silverberg, Michael J, Horberg, Michael A, Althoff, Keri N, Nijhawan, Ank E, McGinnis, Kathleen A, Lee, Jennifer S, Rabkin, Charles S, Napravnik, Sonia, Li, Jun, Castilho, Jessica L, Shen, Changyu, and Jain, Salvia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Lymphoma, Sexually Transmitted Infections, Lymphatic Research, Infectious Diseases, Hematology, Rare Diseases, HIV/AIDS, Cancer, Acquired Immunodeficiency Syndrome, Hodgkin Disease, Humans, Lymphoma, AIDS-Related, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, T-Lymphocytes, Cardiovascular medicine and haematology
Abstract

There are no studies comparing the prognosis for mature T-cell lymphoma (TCL) in people with HIV (PWH) to people without HIV (PWoH) and to AIDS-defining B-cell lymphomas (A-BCLs) in the modern antiretroviral therapy era. North American AIDS Cohort Collaboration on Research and Design and Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment are cohorts that enroll patients diagnosed with HIV and TCL, respectively. In our study, 52, 64, 101, 500, and 246 PWH with histologic confirmation of TCL, primary central nervous system lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), and Hodgkin's lymphoma (HL), respectively, and 450 TCLs without HIV were eligible for analysis. At the time of TCL diagnosis, anaplastic large-cell lymphoma (ALCL) was the most common TCL subtype within PWH. Although PWH with TCL diagnosed between 1996 and 2009 experienced a low 5-year survival probability at 0.23 (95% confidence interval [CI]: 0.13, 0.41), we observed a marked improvement in their survival when diagnosed between 2010 and 2016 (0.69; 95% CI: 0.48, 1; P = .04) in contrast to TCLs among PWoH (0.45; 95% CI: 0.41, 0.51; P = .53). Similarly, PWH with ALCLs diagnosed between 1996 and 2009 were associated with a conspicuously inferior 5-year survival probability (0.17; 95% CI: 0.07, 0.42) and consistently lagged behind A-BCL subtypes such as Burkitt's (0.43; 95% CI:0.33, 0.57; P = .09) and DLBCL (0.17; 95% CI: 0.06, 0.46; P = .11) and behind HL (0.57; 95% CI: 0.50, 0.65; P < .0001). Despite a small number, those diagnosed between 2010 and 2016 experienced a remarkable improvement in survival (0.67; 95% CI: 0.3, 1) in comparison with PWoH (0.76; 95% CI: 0.66, 0.87; P = .58). Thus, our analysis confirms improved overall survival for aggressive B- and T-cell malignancies among PWH in the last decade.

Published
2022

7. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Author

Hapgood, Greg, Civallero, Monica, Stepanishyna, Yana, Vose, Julie, Cabrera, Monica Elena, Advani, Ranjana H., Pileri, Stefano A., Manni, Martina, Horwitz, Steven M., Foss, Francine M., Hitz, Felicitas, Radford, John, Dlouhy, Ivan, Chiattone, Carlos, Kim, Won Seog, Skrypets, Tetiana, Nagler, Arnon, Trotman, Judith, Luminari, Stefano, and Federico, Massimo

Published
2023
Full Text
View/download PDF

9. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations

Author

Ren, Jingjing, Qu, Rihao, Rahman, Nur-Taz, Lewis, Julia M., King, Amber Loren Ong, Liao, Xiaofeng, Mirza, Fatima N., Carlson, Kacie R., Huang, Yaqing, Gigante, Scott, Evans, Benjamin, Rajendran, Barani Kumar, Xu, Suzanne, Wang, Guilin, Foss, Francine M., Damsky, William, Kluger, Yuval, Krishnaswamy, Smita, and Girardi, Michael

Published
2023
Full Text
View/download PDF

11. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).

Author

Theprungsirikul, Poy, primary, Yu, Mansen, additional, Rall, Kerri, additional, Matthews, Martin, additional, Neparidze, Natalia, additional, Parker, Terri L., additional, Browning, Sabrina, additional, Anderson, Tara, additional, Stevens, Erica, additional, Foss, Francine M., additional, Gowda, Lohith, additional, Pillai, Manoj, additional, Isufi, Iris, additional, Seropian, Stuart, additional, Mirza, Sayeef, additional, and Bar, Noffar, additional

Published
2024
Full Text
View/download PDF

12. Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Author

O'Brien, Susan, Patel, Manish, Kahl, Brad S, Horwitz, Steven M, Foss, Francine M, Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan, Jain, Nitin, Allen, Kerstin, Faia, Kerrie, Douglas, Mark, Stern, Howard M, Sweeney, Jennifer, Kelly, Patrick, Kelly, Virginia, and Flinn, Ian

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Hematology, Orphan Drug, Rare Diseases, Lymphoma, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Female, Humans, Isoquinolines, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neutropenia, Phosphoinositide-3 Kinase Inhibitors, Purines, Remission Induction, Transaminases, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-naïve (TN) CLL. Per protocol, TN patients were at least 65 years old or had a del(17p)/TP53 mutation. Duvelisib was administered twice daily (BID) in 28-day cycles at doses of 8-75 mg in RR patients (n = 55) and 25 mg in TN patients (n = 18.) Diarrhea was the most common nonhematologic AE (TN 78%, RR 47%); transaminase elevations the most frequent lab-abnormality AE (TN 33.3%, RR 30.9%); and neutropenia the most common ≥grade 3 AE (RR 44%, TN 33%). The overall response rates were 56.4% for RR patients (1.8% CR, 54.5% PR) and 83.3% for TN patients (all PRs); median response duration was 21.0 months in RR patients but was not reached for TN patients. Based upon phase 1 efficacy, pharmacodynamics, and safety, duvelisib 25 mg BID was selected for further investigation in a phase 3 study in RR CLL/SLL.

Published
2018

15. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Author

Olsen, Elise A., Whittaker, Sean, Willemze, Rein, Pinter-Brown, Lauren, Foss, Francine, Geskin, Larisa, Schwartz, Lawrence, Horwitz, Steven, Guitart, Joan, Zic, John, Kim, Youn H., Wood, Gary S., Duvic, Madeleine, Ai, Wei, Girardi, Michael, Gru, Alejandro, Guenova, Emmanuella, Hodak, Emmilia, Hoppe, Richard, Kempf, Werner, Kim, Ellen, Lechowicz, Mary Jo, Ortiz-Romero, Pablo, Papadavid, Evangelia, Quaglino, Pietro, Pittelkow, Mark, Prince, H. Miles, Sanches, Jose Antonio, Sugaya, Makoto, Vermeer, Maarten, Zain, Jasmine, Knobler, Robert, Stadler, Rudolf, Bagot, Martine, and Scarisbrick, Julia

Published
2022
Full Text
View/download PDF

21. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma.

Author

Goyal, Amrita and Foss, Francine

Subjects
CELL transplantation, CUTANEOUS T-cell lymphoma, SEZARY syndrome, CELLULAR therapy, T-cell lymphoma, CD30 antigen, STEM cell transplantation, MYCOSIS fungoides, ALLOIMMUNITY
Abstract

Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell lymphoma. Although many available treatments offer temporary disease control, allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only curative treatment option for advanced stage MF and SS. CAR T-cell therapy is a promising new avenue for treatment. In this review, we discuss the evidence supporting the use of allo-HSCT for the treatment of MF/SS, including disease status at the time of transplant, conditioning regimen, total body irradiation (TBI), and donor lymphocyte infusion (DLI). We also address the potential role for CAR T-cell therapy in CTCL. Allo-HSCT is an effective treatment for patients with advanced MF and SS. However, significant research is required to determine optimal treatment protocols. Data support the use of reduced-intensity conditioning regimens and suggests that the use of TBI for debulking of skin disease may result in more durable remissions. Donor lymphocyte infusions (DLI) appear to be particularly effective in inducing complete remission in MF/SS patients with relapsed or residual disease. Challenges with CAR-T therapies in T-cell lymphoma include T-cell fratricide due to shared antigens on malignant and nonmalignant T-cells, penetrance into the skin compartment, and CAR-T cell persistence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL

Author

Rasheed, Yusuf, primary, Mirza, Abu-Sayeef, additional, Pine, Alexander, additional, Hamouche, Ramzi, additional, Leveille, Etienne, additional, Goshua, George, additional, Gu, Sean, additional, Liu, Yuxin, additional, Vanoudenhove, Jennifer, additional, Bar, Noffar, additional, Neparidze, Natalia, additional, Foss, Francine, additional, Gowda, Lohith, additional, Isufi, Iris, additional, Halene, Stephanie, additional, Lee, Alfred, additional, and Seropian, Stuart, additional

Published
2023
Full Text
View/download PDF

23. P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL

Author

Mirza, Abu-Sayeef, primary, Pine, Alexander, additional, Hamouche, Ramzi, additional, Rasheed, Yusuf, additional, Leveille, Etienne, additional, Goshua, George, additional, Gu, Sean, additional, Liu, Yuxin, additional, Vanoudenhove, Jennifer, additional, Bar, Noffar, additional, Neparidze, Natalia, additional, Foss, Francine, additional, Gowda, Lohith, additional, Isufi, Iris, additional, Halene, Stephanie, additional, Lee, Alfred, additional, and Seropian, Stuart, additional

Published
2023
Full Text
View/download PDF

24. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Author

Murthy, Hemant S., Ahn, Kwang Woo, Estrada-Merly, Noel, Alkhateeb, Hassan B., Bal, Susan, Kharfan-Dabaja, Mohamed A., Dholaria, Bhagirathbhai, Foss, Francine, Gowda, Lohith, Jagadeesh, Deepa, Sauter, Craig, Abid, Muhammad Bilal, Aljurf, Mahmoud, Awan, Farrukh T., Bacher, Ulrike, Badawy, Sherif M., Battiwalla, Minoo, Bredeson, Chris, Cerny, Jan, Chhabra, Saurabh, Deol, Abhinav, Diaz, Miguel Angel, Farhadfar, Nosha, Freytes, César, Gajewski, James, Gandhi, Manish J., Ganguly, Siddhartha, Grunwald, Michael R., Halter, Joerg, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Jimenez-Jimenez, Antonio Martin, Kalaycio, Matt, Kamble, Rammurti, Krem, Maxwell M., Lazarus, Hillard M., Lazaryan, Aleksandr, Maakaron, Joseph, Munshi, Pashna N., Munker, Reinhold, Nazha, Aziz, Nishihori, Taiga, Oluwole, Olalekan O., Ortí, Guillermo, Pan, Dorothy C., Patel, Sagar S., Pawarode, Attaphol, Rizzieri, David, Saba, Nakhle S., Savani, Bipin, Seo, Sachiko, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wirk, Baldeep, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, and Saber, Wael

Published
2022
Full Text
View/download PDF

26. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Author

Horwitz, Steven M., Koch, Raphael, Porcu, Pierluigi, Oki, Yasuhiro, Moskowitz, Alison, Perez, Megan, Myskowski, Patricia, Officer, Adam, Jaffe, Jacob D., Morrow, Sara N., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kelly, Patrick, Kelly, Virginia, Aster, Jon C., Weaver, David, Foss, Francine M., and Weinstock, David M.

Published
2018
Full Text
View/download PDF

30. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Hamadani, Mehdi, Reimer, Peter, Gisselbrecht, Christian, d'Amore, Francesco, Jantunen, Esa, Ishida, Takashi, Bazarbachi, Ali, Foss, Francine, Advani, Ranjana, Fenske, Timothy S., Lazarus, Hillard M., Friedberg, Jonathan W., Aljurf, Mahmoud, Sokol, Lubomir, Tobinai, Kensei, Tse, Eric, Burns, Linda J., Chavez, Julio C., Reddy, Nishitha M., Suzuki, Ritsuro, Ahmed, Sairah, Nademanee, Auayporn, Mohty, Mohamad, Gopal, Ajay K., Fanale, Michelle A., Pro, Barbara, Moskowitz, Alison J., Sureda, Anna, Perales, Miguel Angel, Carpenter, Paul A., and Savani, Bipin N.

Published
2017
Full Text
View/download PDF

31. Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

33. Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

34. Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

35. Data from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., primary, William, Basem M., primary, Brammer, Jonathan E., primary, Smith, Sonali M., primary, Prica, Anca, primary, Zain, Jasmine M., primary, Tuscano, Joseph M., primary, Shah, Harsh, primary, Mehta-Shah, Neha, primary, Geethakumari, Praveen Ramakrishnan, primary, Wang, Ben X., primary, Zantinge, Stephanie, primary, Wang, Lisa, primary, Zhang, Ling, primary, Boutrin, Anmarie, primary, Zhao, Weiguang, primary, Cheng, Lily, primary, Standifer, Nathan, primary, Hewitt, Lisa, primary, Enowtambong, Enowmpey, primary, Shao, Weiping, primary, Sharma, Shringi, primary, Carlesso, Gianluca, primary, Moscow, Jeffrey A., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

37. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States

Author

Hsi, Eric D., Horwitz, Steven M., Carson, Kenneth R., Pinter-Brown, Lauren C., Rosen, Steven T., Pro, Barbara, Federico, Massimo, Gisselbrecht, Christian, Schwartz, Marc, Bellm, Lisa A., Acosta, Mark, Collie, Angela M., Gruver, Aaron M., Grzywacz, Bartosz J., Turakhia, Samir, Shustov, Andrei R., Advani, Ranjana H., Feldman, Tatyana, Lechowicz, Mary Jo, Smith, Sonali M., Lansigan, Frederick, Tulpule, Anil, Craig, Michael D., Greer, John P., Kahl, Brad S., Leach, Joseph W., Morganstein, Neil, Casulo, Carla, Park, Steven I., and Foss, Francine M.

Published
2017
Full Text
View/download PDF

46. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Author

Chavez, Julio C., primary, Foss, Francine M., additional, William, Basem M., additional, Brammer, Jonathan E., additional, Smith, Sonali M., additional, Prica, Anca, additional, Zain, Jasmine M., additional, Tuscano, Joseph M., additional, Shah, Harsh, additional, Mehta-Shah, Neha, additional, Geethakumari, Praveen Ramakrishnan, additional, Wang, Ben X., additional, Zantinge, Stephanie, additional, Wang, Lisa, additional, Zhang, Ling, additional, Boutrin, Anmarie, additional, Zhao, Weiguang, additional, Cheng, Lily, additional, Standifer, Nathan, additional, Hewitt, Lisa, additional, Enowtambong, Enowmpey, additional, Shao, Weiping, additional, Sharma, Shringi, additional, Carlesso, Gianluca, additional, Moscow, Jeffrey A., additional, and Siu, Lillian L., additional

Published
2023
Full Text
View/download PDF

47. Outcomes after Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplant in Patients with Mature T Cell Lymphomas Based on Disease Status at Transplant: A Single Institution Experience

Author

Mirza, Abu-Sayeef, primary, Hamouche, Ramzi, additional, Di, Mengyang, additional, Isufi, Iris, additional, Bar, Noffar, additional, Sethi, Tarsheen, additional, Gowda, Lohith, additional, Perreault, Sarah, additional, Roberts, Kenneth, additional, Seropian, Stuart, additional, and Foss, Francine M., additional

Published
2023
Full Text
View/download PDF

48. Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen

Author

Di, Mengyang, primary, Mirza, Abu-Sayeef, additional, Hamouche, Ramzi, additional, Isufi, Iris, additional, Bar, Noffar, additional, Sethi, Tarsheen, additional, Gowda, Lohith, additional, Perreault, Sarah, additional, Roberts, Kenneth, additional, Seropian, Stuart, additional, and Foss, Francine M., additional

Published
2023
Full Text
View/download PDF

49. Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience

Author

Hamouche, Ramzi, primary, Mirza, Abu-Sayeef, additional, Di, Mengyang, additional, Isufi, Iris, additional, Bar, Noffar, additional, Sethi, Tarsheen, additional, Gowda, Lohith, additional, Perreault, Sarah, additional, Roberts, Kenneth, additional, Seropian, Stuart, additional, and Foss, Francine M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results